Eli Lilly is intensifying its focus on the obesity medicine market by launching the Employer Connect platform to enhance access to its weight loss drugs, Zepbound and Mounjaro, through U.S. employers. This strategic move aims to counter fierce competition from Novo Nordisk, as analysts forecast 2026 revenues reaching between $80 billion and $83 billion, driven predominantly by GLP-1 products. However, Eli Lilly faces legal challenges concerning past product liabilities, adding layers of uncertainty to its financial outlook.
“Eli Lilly also donated $1,000 to the missionary group, which they used to build a school. Bouw returned from Indonesia in 1960 and seemed to have spent the rest of his life doing good.”
“Novo Nordisk is losing to Eli Lilly in the fiercely competitive weight loss market. But one of the company's mid-stage assets could help it remain a key player.”
“When you step back, it seems like Eli Lilly is priced for perfection, while investors largely ignore rivals Novo Nordisk and Pfizer. That could be an opportunity, because the drug sector is highly competitive and driven by innovation.”
“Eli Lilly is going beyond its efforts to sell its obesity drug Zepbound directly to patients, and is now trying to target employers.”
“Weight-loss drugs are becoming a workplace benefit. Eli Lilly just launched a platform designed to help employers offer Zepbound to workers.”
“GLP-1 drugs are all the rage on Wall Street today, with demand for these weight loss products expected to be strong for years to come. That's helped to supercharge Eli Lilly's (NYSE: LLY) growth and its stock price.”
“They are now the leading GLP-1 drugs, with 2025 revenue growth of 99% and 175%, respectively. Together, they account for 56% of Eli Lilly's top line. Eli Lilly has a lot riding on the success of these two drugs.”
“The price-to-earnings (P/E) ratio is 44, and the dividend yield is a miserly 0.6%. It looks like Eli Lilly is priced for perfection. Wall Street has placed a very rich valuation on the stock.”
“GLP-1 drugs are all the rage on Wall Street today, with demand for these weight loss products expected to be strong for years to come. That's helped to supercharge Eli Lilly's growth and its stock price.”
“Eli Lilly has a lot riding on the success of these two drugs.”
“It looks like Eli Lilly is priced for perfection.”
“Eli Lilly isn't bad, just expensive.”
